Regulatory Writing AI Use Cases: A Practical Playbook

TL;DR:

• AI accelerates regulatory writing tasks like first-draft creation, quality checking, and eCTD assembly using traceability-focused models. It improves efficiency and consistency but requires strong data infrastructure, validation, and governance to ensure compliance and inspectability. Successful implementation depends on careful pilot testing, robust documentation, and integrating human oversight throughout the process.

The highest-impact regulatory writing AI use cases available to US teams right now are: first-draft generation for Clinical Study Reports (CSRs), table-listing-figure (TLF) to narrative conversion, eCTD module assembly and cross-module linkage, automated QC and consistency checking, evidence extraction with traceable citations, safety narrative summarization (PSUR/DSUR), redaction and de-identification workflows, and change-impact analysis across the CTD network. These aren't theoretical. Teams using purpose-built platforms report substantially faster document authoring under the right data conditions, though that ceiling depends entirely on source data quality and traceability controls being in place before the model touches a single table.

Ranked by impact on time-to-submission and auditability:

• TLF-to-narrative conversion — highest volume, most repeatable, fastest ROI
• Automated QC and cross-document consistency — catches errors humans miss at scale
• CSR first-draft generation — large time savings, requires strong data readiness
• eCTD assembly and cross-module linkage — reduces formatting cycles and cross-reference errors
• Safety summarization (PSUR/DSUR) — structured inputs make this well-suited for AI
• Evidence extraction and traceable citations — foundational for audit-ready outputs
• Redaction and de-identification — high accuracy, low creative risk
• Change-impact analysis — valuable at scale, complex to implement

TL;DR: Start with traceability-first pilots — table mapping plus retrieval-augmented generation (RAG) — and build human-in-the-loop QC gates before scaling any use case.

Table of Contents

• Why AI is changing regulatory writing right now
• Where AI helps most — and where it still needs you
• Practical AI use cases, task by task
• What are the biggest risks of AI in regulatory writing?
• Which tool categories should regulatory teams evaluate?
• How do you keep AI outputs verifiable and audit-ready?
• How do you pilot AI in a regulatory writing team?
• How Haiphai operationalizes AI for regulated regulatory drafting
• What should regulatory teams watch in the next 12–24 months?
• Three rules for using AI sensibly in regulatory writing
• Key Takeaways
• The gap between AI's promise and what actually matters in regulatory writing
• Haiphai helps biotech teams build regulatory AI workflows that hold up at inspection
• Useful sources and regulatory references
• FAQ

Why AI is changing regulatory writing right now

Three converging capabilities make today's AI tools genuinely useful for regulatory documentation rather than just impressive in demos: large language models (LLMs) that can read and generate structured scientific prose, retrieval-augmented generation (RAG) that grounds outputs in verified source documents, and agentic workflow automation that can orchestrate multi-step tasks like eCTD assembly without constant human hand-holding.

LLMs (GPT-4 family, Anthropic Claude) are the generation layer. They read protocol text, statistical tables, and annotated outputs, then produce coherent narrative. RAG is the control layer: it forces the model to retrieve and cite specific source passages before generating, which is what separates a useful regulatory co-pilot from a hallucination machine. Agentic AI adds orchestration: the ability to chain tasks (extract table → map to template → generate paragraph → flag inconsistency → route for review) without a human triggering each step. Domain-tuned models are fine-tuned on regulatory corpora — ICH guidelines, FDA guidance documents, eCTD specifications — so they understand the vocabulary and structure without extensive prompting.

These capabilities map directly to regulatory tasks. RAG handles evidence linking in CSRs. Agentic pipelines manage eCTD cross-module updates. Domain-tuned models reduce the prompt engineering burden for CMC sections. The regulatory writing role is shifting from content generation toward AI-augmented strategy, with writers spending more time on evidence curation and clinical emphasis review than on typing.

On the regulatory side, the FDA has signaled that explainability and traceability are non-negotiable. The agency's proposed framework for AI credibility in drug and biological product submissions makes clear that any AI-assisted content must be documentable, auditable, and attributable to verifiable sources.

Haiphai's operational framing fits squarely here: working backward from submission readiness to identify where AI can be inserted with full governance controls, rather than deploying tools and hoping the compliance layer catches up.

Where AI helps most — and where it still needs you

AI reliably improves four things in regulatory documentation: speed on high-volume repetitive tasks, consistency across large document sets, reuse of approved language and templates, and automated QC that catches cross-document discrepancies at a scale no human team can match.

In practice, that means a TLF-to-narrative pipeline can convert dozens of statistical tables into draft paragraphs overnight. A consistency checker can flag every instance where a p-value in the body text doesn't match the corresponding table — something that slips through manual review more often than teams admit. Template-driven reuse means approved boilerplate for informed consent forms or CMC sections doesn't get rewritten from scratch each time, reducing both effort and the risk of introducing variation.

The limits are real and worth naming plainly. Hallucination is the most dangerous: models will generate plausible-sounding text that misrepresents a numeric result if the source table is ambiguous or the retrieval step fails. Reasoning gaps across large numeric tables are common — models struggle with multi-variable interactions in complex efficacy tables without explicit mapping logic. Model drift means a model that performed well on one protocol may behave differently on a structurally different one. Native traceability is absent in general-purpose LLMs: ChatGPT or Claude used directly via API will not automatically link every sentence to its source passage.

The task-risk split is roughly this: TLF conversion, redaction, QC checks, and template-based CMC sections can be heavily automated with appropriate controls. CSR narrative, clinical emphasis decisions, safety signal interpretation, and any content that requires medical judgment must remain human-led, with AI in a drafting-support role only.

Pro Tip: Before running any generative model on regulatory source data, standardize your TLFs and annotated outputs into a canonical format. Automating messy source data produces hallucinated drafts that cost more time to fix than writing manually.

Practical AI use cases, task by task

AI regulatory writing platforms now cover the full drug lifecycle from IND to NDA/BLA, automating cross-module connectivity and table mapping. Here's how each use case breaks down for a working regulatory team.

1. TLF-to-narrative conversion for CSRs. The model reads canonical TLFs (tables, listings, figures) and generates draft narrative paragraphs aligned to ICH E3 structure. Inputs: standardized CDISC-compliant outputs, protocol, SAP. Benefit: eliminates the most time-consuming mechanical writing task in a CSR. Human checks: numeric verification against source tables, clinical emphasis review, sign-off by a qualified medical writer.

2. eCTD module assembly and cross-module linkage. Agentic platforms automate formatting, cross-reference generation, and consistency checks across CTD modules 2–5. Inputs: draft module content, eCTD backbone, cross-reference map. Benefit: reduces formatting cycles and catches broken cross-references before submission. Human checks: final structural review, hyperlink validation, regulatory affairs sign-off.

3. CMC document drafting. Template-driven generation for drug substance and drug product sections using approved language libraries. Inputs: batch records, analytical methods, specifications. Benefit: consistent language across manufacturing sites and product variants. Human checks: chemistry review, specification verification, QA approval.

4. Informed consent and patient-facing materials. AI drafts plain-language versions of consent forms and lay summaries from clinical protocol text. Inputs: protocol, IB, prior consent templates. Benefit: faster first drafts at appropriate reading level; consistency across sites. Human checks: IRB requirements review, readability confirmation, patient advocate input where applicable.

5. Automated QC and cross-document consistency. Style checkers and cross-reference validators scan the full submission package for inconsistencies: mismatched p-values, inconsistent drug names, broken cross-references, style guide violations. Inputs: full document set, style guide, cross-reference map. Benefit: catches errors that slip through manual review. Human checks: triage of flagged items, judgment on clinical significance.

6. Safety narrative summarization (PSUR/DSUR). AI aggregates adverse event data and generates structured safety narratives aligned to ICH E2C/E2F templates. Inputs: safety database exports, prior PSUR, line listings. Benefit: faster first draft of periodic reports. Human checks: signal interpretation, benefit-risk assessment, pharmacovigilance physician review.

7. Redaction and de-identification. Named-entity recognition models identify and redact PII, proprietary information, and commercially sensitive data from clinical study reports and regulatory submissions. Inputs: unredacted documents, redaction criteria. Benefit: consistent, auditable redaction with a full log of what was removed and why. Human checks: legal review of redaction scope, spot-check of edge cases.

8. Change-impact analysis across the CTD network. When a protocol amendment or manufacturing change occurs, AI maps which downstream documents require updates and generates a change-impact report. Inputs: change description, document inventory, cross-reference map. Benefit: prevents missed updates that cause submission deficiencies. Human checks: regulatory affairs review of scope, prioritization of updates.

9. Evidence extraction and traceable citations. RAG-based systems extract supporting evidence from clinical study reports, published literature, and regulatory precedents, linking each claim to its source passage. Inputs: source document library, query set. Benefit: every generated claim carries an inline citation reviewers can verify. Human checks: evidence relevance review, citation accuracy check.

10. Living documents and automated updates. For investigator brochures, RSIs, and other living documents, AI monitors source data for triggering changes and drafts update sections. Inputs: source data feeds, document version history, update triggers. Benefit: reduces the lag between new data and document updates. Human checks: medical review of new content, version control sign-off.

Note: Document authoring speedup claims (up to 95% faster) are conditional on data readiness and traceability controls, as emphasized by vendors and platform descriptions.

These are illustrative ranges based on vendor and platform descriptions. Actual results depend on data readiness, traceability controls, and team workflow maturity.

What are the biggest risks of AI in regulatory writing?

The single biggest adoption risk is auditability: if you cannot show a reviewer exactly which source passage generated a specific sentence, the draft is a liability, not an asset. Speed gains evaporate when validation teams spend weeks reconstructing provenance that the authoring tool never captured.

The FDA's proposed credibility framework for AI in drug submissions makes this explicit. The agency expects documentation of how AI models were used, what data they were trained or fine-tuned on, and how outputs were validated before inclusion in a submission. This isn't a future requirement to monitor; it's the standard teams should be designing to now.

Risk mitigation checklist:

• Source-linked RAG: every generated sentence must carry an inline citation to its source passage, expandable to full text and metadata
• Immutable audit logs: timestamped records of model version, prompt, input data, and output for every generation event
• Human-in-the-loop review gates: no AI-generated content advances to submission without qualified human sign-off at defined checkpoints
• Model testing and validation: document model performance on representative regulatory tasks before deployment; retest after model updates
• Access controls and data governance: clinical data used for AI generation must be hosted in compliant environments (US-based, HIPAA-aligned where applicable); no patient-level data in general-purpose cloud APIs without a BAA
• IP and data leakage controls: enterprise API agreements or on-premise deployment for proprietary compound data; audit what data leaves your environment

Organizational risks are just as real. Most regulatory writing teams lack prompt engineering skills, and the gap between a well-structured prompt and a poorly structured one can mean the difference between a usable draft and a hallucinated one. Change management is harder than the technology: writers who feel their expertise is being replaced will resist workflows they should be designing. Cross-team responsibilities need explicit definition — who owns the RAG knowledge base? Who validates model outputs? Who updates the SOP when the model changes?

On data privacy: US-regulated clinical data used in AI generation should be hosted in US-based, HIPAA-compliant environments. De-identification before any data enters a general-purpose LLM API is the minimum standard. For Phase III data or commercially sensitive compound information, on-premise or private cloud deployment is the more defensible posture. The AI Act's technical documentation requirements — though EU-originated — are already influencing how US-facing enterprises think about AI BOMs and traceability documentation, particularly for global submissions.

Which tool categories should regulatory teams evaluate?

Four to six tool categories cover the full regulatory AI stack, and each does a distinct job: LLM APIs handle generation, domain-tuned models reduce prompt complexity, RAG engines enforce source linkage, agentic authoring platforms orchestrate multi-step workflows, QC/validation tools catch errors post-generation, and integration layers connect everything to existing regulatory systems.

• LLM APIs (GPT-4 family, Anthropic Claude): the generation backbone. OpenAI's GPT-4 family and Anthropic's Claude are the two most evaluated options for enterprise regulatory use. Both offer enterprise agreements with data privacy controls. Neither provides native regulatory traceability out of the box — that requires a RAG layer on top.
• Domain-tuned models: fine-tuned on ICH guidelines, FDA guidance, and eCTD specifications. Reduce prompt engineering burden and improve output structure for regulatory deliverables. Availability varies; some are embedded in authoring platforms.
• RAG / knowledge-base systems: the traceability layer. These systems index your source documents (protocols, TLFs, prior submissions) and force the generation model to retrieve and cite before generating. Without this, inline citations are absent and validation is manual.
• Regulatory authoring platforms / agentic AI: end-to-end platforms that combine generation, template management, cross-module linkage, and QC in a single workflow. These are the closest to a production-ready solution for most teams, though they require significant data preparation upfront.
• QC and validation tools: standalone or embedded checkers that scan outputs for style violations, cross-document inconsistencies, and broken cross-references. Some integrate directly with eCTD publishing tools.
• Integration and orchestration layers: APIs and middleware that connect authoring platforms to CTMS, safety databases, and document management systems. Critical for living documents and automated update workflows.

For US teams, data residency matters. Enterprise licensing from OpenAI and Anthropic includes US-based hosting options, but verify BAA availability for any workflow touching patient data. Purpose-built regulatory platforms often offer private cloud or on-premise deployment for GxP environments. Required capabilities for any regulatory-grade tool: inline traceability, version control, evidence linking, and immutable audit logs. Human oversight level scales inversely with task risk — high automation for redaction and QC, mandatory human review for clinical narrative and safety interpretation.

How do you keep AI outputs verifiable and audit-ready?

The design principle is simple: every claim in a generated document must trace back to a specific, timestamped source passage. Building that traceability into the pipeline from the start is far cheaper than retrofitting it after a reviewer asks where a number came from.

The recommended data flow runs: source systems (CTMS, safety DB, statistical outputs) → canonical tables and transfer files → knowledge store → RAG layer → authoring engine → human review → immutable version record. Each handoff should carry provenance metadata: what source document, what version, what extraction timestamp. The RAG layer is where traceability is enforced: the model retrieves a passage, cites it inline, and the citation expands to the full source text and metadata when a reviewer clicks it. Platforms that embed this inline citation model reduce downstream validation cycles significantly because reviewers can verify claims directly rather than hunting through source files.

Table mapping for numeric TLFs deserves specific attention. Models that receive a raw PDF table will often misread column headers, merge rows, or transpose values. The correct approach: extract TLF data into a structured intermediate format (JSON or structured Markdown), validate the extraction against the source, then feed the structured data to the generation model with explicit column-to-narrative mapping instructions. This is where data readiness for clinical pipelines intersects with authoring quality — clean, structured diagnostic and statistical outputs upstream mean fewer extraction errors downstream.

Validation artifacts to keep for regulatory inspection: signed review logs with reviewer credentials and timestamps, evidence pointers linking each generated paragraph to its source passage, test cases documenting numeric verification checks, and model validation records showing performance on representative regulatory tasks before deployment.

How do you pilot AI in a regulatory writing team?

Start small, validate hard, then scale with controls. A 30–90 day pilot on a single high-value, low-risk use case — TLF-to-narrative conversion for a completed study is the standard starting point — gives you real performance data without submission risk.

1. Days 1–15: Data readiness and scoping. Identify one completed study with clean, CDISC-compliant TLFs. Define the pilot scope (one CSR section, e.g., efficacy narrative). Assign roles: data owner, prompt engineer, medical writer reviewer, regulatory affairs sign-off. Document the baseline: how long does manual drafting of this section take?

2. Days 16–30: Tool selection and environment setup. Select the authoring tool or RAG stack. Configure data ingestion from canonical TLFs. Set up the audit log and version control. Run the first generation on a non-submission document to validate output quality and traceability.

3. Days 31–60: Pilot generation and acceptance testing. Generate draft paragraphs for the scoped section. Run acceptance criteria: numeric accuracy check (every figure in the draft matches the source table), traceability check (every sentence carries an expandable inline citation), style check (output conforms to house style guide). Document pass/fail rates and reviewer time spent on corrections.

4. Days 61–90: Review, measure, and gate decision. Compile metrics: time-to-first-draft reduction, percentage of auto-generated paragraphs requiring zero edits, reviewer hours saved, cross-document inconsistencies caught by automated QC. Apply gating criteria: if numeric accuracy is below 98% or traceability coverage is below 100%, do not advance to production. Fix the data pipeline or tool configuration first.

Scaling checklist:

• Governance: update SOPs to define AI use, review requirements, and sign-off responsibilities
• Training: prompt engineering workshops for writers; verification protocol training for reviewers
• Monitoring: schedule quarterly model performance reviews; define retraining triggers
• SOP updates: version-control all changes; link to validation records

Success metrics to track:

• Time-to-first-draft reduction (target: 40–60% for TLF-to-narrative)
• Percentage of auto-generated paragraphs requiring more than zero edits (lower is better)
• Reviewer hours saved per CSR
• Cross-document inconsistencies caught before QC review
• Audit-ready evidence coverage (percentage of claims with inline citations)

Gating criteria for pilot to production: numeric accuracy ≥ 98%, traceability coverage = 100%, reviewer sign-off rate within defined SLA, zero unresolved audit log gaps. If any criterion fails, the pilot extends — it does not advance.

How Haiphai operationalizes AI for regulated regulatory drafting

Haiphai's approach to regulatory AI isn't about deploying a tool and measuring word count. Clients reclaim up to 18 months of operational time on the path to approval by starting from submission readiness and working backward to identify exactly where AI can be inserted with full governance controls. That framing changes what gets piloted first: not the flashiest use case, but the one with the cleanest data and the clearest audit trail.

The before/after impact follows a consistent pattern: teams that previously spent weeks on TLF-to-narrative conversion for a single CSR section reduce that to days, with reviewer time shifting from drafting to verification. The operational time recovered compounds across the submission timeline, which is what drives the valuation and funding impact Haiphai's clients care about.

Haiphai's operational approach for regulatory AI pilots:

• Data readiness first: canonicalize and standardize TLFs and source documents before any model touches them; this is the single most important determinant of output quality
• Template-driven authoring: approved language libraries and ICH-aligned templates reduce generation variance and make outputs easier to review
• Traceability-first RAG: every generation event is grounded in retrieved source passages with inline citations that expand to full text and metadata
• Human-in-the-loop validation: defined review gates at each stage; no AI output advances without qualified sign-off
• Change orchestration: when source data changes, the system maps downstream document impacts and routes updates for review rather than leaving writers to track changes manually

Haiphai's trust and transparency approach includes audit logs, inline evidence links, and governance documentation that supports regulatory inspection readiness. For teams evaluating AI augmentation in regulatory affairs, the operational partner model means the governance layer is built in from day one, not bolted on after the first submission deficiency.

What should regulatory teams watch in the next 12–24 months?

The single highest-impact watch item is traceability requirements hardening into formal standards. The FDA's credibility framework for AI in submissions is moving from proposed to expected practice, and the EU AI Act's technical documentation requirements — including AI bills of materials — are already influencing how global submissions are structured. US teams that treat traceability as optional now will face a harder retrofit later.

Near-term developments to monitor:

• FDA credibility framework finalization: documentation of AI model use in submissions will shift from best practice to required; teams should start building those records now
• AI BOMs as a submission artifact: the concept of an AI bill of materials — documenting which models, versions, and training data contributed to a submission — is gaining traction in EU-facing regulatory circles and will likely influence FDA expectations
• RAG improvements for numeric tables: current RAG systems still struggle with complex multi-variable tables; vendors are actively improving structured data retrieval, and this will expand the safe automation zone for efficacy and safety narratives
• Built-in provenance in authoring platforms: the next generation of regulatory authoring tools will embed provenance tracking at the generation level rather than requiring a separate RAG layer; this will lower implementation complexity significantly
• Writer role evolution: the regulatory writer's job is becoming evidence curator and prompt engineer. Teams that invest in these skills now — systematic verification against source records and human-in-the-loop workflow design — will have a structural advantage

How to prepare: invest in canonical data infrastructure (clean, structured TLFs and source documents) before selecting tools. Update SOPs to include AI use documentation. Start model validation processes now, even for pilots, so the records exist when inspectors ask. The teams that treat AI governance as a submission-readiness asset rather than a compliance burden will move faster, not slower.

Three rules for using AI sensibly in regulatory writing

AI delivers real, measurable value in regulatory documentation when it is deployed with traceability-first design, human-in-the-loop validation, and data readiness as prerequisites — not afterthoughts.

• Start with high-value, low-risk tasks: TLF-to-narrative conversion and automated QC are the right entry points; they deliver the largest time savings with the most manageable validation burden
• Require inline evidence links: no generated content should advance without an expandable citation to its source passage; this is the single control that separates a regulatory-grade output from a liability
• Measure what matters for submission readiness: track reviewer hours saved, numeric accuracy rates, and audit-ready evidence coverage — not word count or draft speed alone

Pilot with governance in place, document the results, and let the evidence drive your scaling decisions.

Key Takeaways

AI delivers the largest regulatory writing gains when traceability-first design, data readiness, and human-in-the-loop validation are built into the workflow from the start, not added after deployment.

The gap between AI's promise and what actually matters in regulatory writing

The conversation about AI in regulatory writing tends to get stuck on two extremes: either breathless claims about 95% faster authoring, or blanket skepticism from teams that tried a general-purpose chatbot and got a hallucinated efficacy table. Both miss the point.

What actually matters isn't how fast a model can generate text. It's whether the output is defensible at inspection. A draft CSR section that took 20 minutes to generate but requires six hours of provenance reconstruction before a reviewer can sign off isn't a win. The teams making real progress are the ones who treated data readiness and traceability as infrastructure investments before they touched a single generation model.

The other thing most articles understate: the organizational change is harder than the technology. Regulatory writers are highly skilled professionals who have spent careers developing judgment about clinical emphasis, safety signal interpretation, and submission strategy. Asking them to become prompt engineers and verification specialists on top of that, without adequate training or role clarity, is a recipe for resistance and poor adoption. The technology works. The change management is where pilots fail.

Haiphai's approach of starting from strategic goals and working backward to identify bottlenecks is the right frame for this. The question isn't "which AI tool should we buy?" It's "where in our submission timeline does AI create the most defensible value, and what governance do we need to capture it?" That's a harder question, and it's the right one.

Haiphai helps biotech teams build regulatory AI workflows that hold up at inspection

Reclaiming 18 months of operational time on the path to approval isn't about deploying the fastest model. It's about knowing which regulatory writing tasks are ready for AI, building the data pipelines and traceability controls that make outputs defensible, and governing the whole workflow so the first inspection doesn't undo the gains.

Haiphai partners with biotech and pharma teams to operationalize traceable AI authoring workflows from the ground up. The work starts with your submission timeline and works backward:

• Data readiness assessment: identify which TLFs and source documents need canonicalization before any model runs
• Workflow design: map AI use cases to your specific regulatory deliverables and define human-in-the-loop review gates
• Governance and SOP development: build the audit trail, version control, and sign-off documentation your submission will need
• Vendor selection support: evaluate authoring platforms and RAG stacks against your data environment and compliance requirements

If your team is planning a regulatory AI pilot, the Haiphai solutions page outlines how the operational partner model works in practice. For teams that want to understand the governance and trust architecture first, Haiphai's trust framework covers the controls that make AI outputs inspection-ready.

Useful sources and regulatory references

These sources are worth bookmarking for evidence and compliance follow-up, particularly for US regulatory teams building AI governance documentation.

• FDA proposed framework for AI credibility in drug submissions: the primary US regulatory signal on what documentation of AI use in submissions will require; essential reading for any team planning a pilot
• FDA guidance on electronic submissions (eCTD): baseline technical requirements for eCTD formatting and cross-module structure; relevant when evaluating eCTD assembly automation
• PPD: AI in Regulatory Medical Writing: professional services analysis of skill shifts and productivity approaches; useful for training and change management planning
• ArXiv: data readiness and generative models: academic grounding for the content-readiness argument; cite this when making the case internally for data preparation investment
• De Jure: iterative LLM self-refinement for regulatory rule extraction: demonstrates that RAG-grounded responses using structured regulatory rule extraction are preferred over unstructured approaches in compliance QA tasks; relevant for teams evaluating RAG architecture choices
• ETHZ: European AI Act technical documentation research: AI BOMs and technical documentation requirements emerging from the AI Act; relevant for US teams with EU submission obligations
• KoHealthLabs: integrated clinical diagnostics for CROs and pharma: practical reference for integrating structured diagnostic and clinical data streams into regulatory documentation pipelines
• Haiphai: AI in regulatory affairs for biotech: operational framing for AI use cases across the regulatory writing lifecycle, with biotech-specific examples

FAQ

What are the best AI use cases for regulatory writing?

TLF-to-narrative conversion, automated QC and cross-document consistency checking, and eCTD assembly are the highest-ROI starting points. They deliver measurable time savings on repeatable tasks while keeping clinical judgment decisions with human reviewers.

How does the FDA view AI-generated content in drug submissions?

The FDA has proposed a credibility framework requiring documentation of how AI models were used, what data they relied on, and how outputs were validated before inclusion in a submission. Teams should build audit trails and traceability records now, before the framework is finalized.

What is the biggest risk of using AI in regulatory documentation?

Auditability is the primary risk. If generated content cannot be traced to a specific source passage, validation teams must reconstruct provenance manually, which offsets the speed gains. Source-linked RAG and immutable audit logs are the core controls.

How long does a regulatory AI pilot typically take?

A well-scoped pilot on a single use case, such as TLF-to-narrative for one CSR section, runs 30–90 days. The first 30 days cover data readiness and tool setup; the middle phase covers generation and acceptance testing; the final phase covers measurement and the gate decision for production.

Does AI replace regulatory writers?

No. The role shifts from content generation to evidence curation, prompt engineering, and verification. Skills like systematic verification against source records and designing human-in-the-loop review workflows are becoming core competencies for regulatory writers working with AI tools.

Recommended

• AI in Regulatory Affairs: The Strongest Augmentation Story in Biotech | HaiPhai
• Solutions | HaiPhai
• Blog | HaiPhai
• What Is AI Augmentation? A Practical Guide for Biotech Leaders | HaiPhai